Nakom Mite (Carbidopa, Levodopa)

Carbidopa/Levodopa, the active ingredient in Nakom Mite, is an Antiparkinson agent presented as an oral tablet formulation for oral use. It is employed to increase central dopamine levels in patients with Parkinson's disease and related Parkinsonian syndromes, helping to improve motor function and reduce rigidity.

GNH USA supplies Nakom Mite as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Customers benefit from reliable logistics and comprehensive technical support.

Carbidopa/Levodopa is indicated for conditions within the Parkinsonian disease spectrum, where it enhances dopaminergic neurotransmission.

- Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity, tremor, and gait disturbances. - Parkinsonian syndrome: alleviates motor deficits associated with secondary Parkinsonism caused by drugs or vascular injury. - Levodopa‑responsive Parkinsonism: provides symptomatic relief in patients who demonstrate a positive response to dopaminergic therapy. - Rest tremor: reduces amplitude and frequency of tremor episodes, improving daily hand function. - Motor fluctuations: helps smooth on‑off periods in advanced disease, enhancing overall functional stability.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset occurring after initial dosing. - Orthostatic hypotension: dizziness or light‑headedness upon standing due to vasodilatory effects. - Headache: transient cranial discomfort often reported during dose titration. - Insomnia: difficulty initiating or maintaining sleep, especially in the evening.

Serious or Rare Side Effects: - Dyskinesia: involuntary, erratic movements that may develop with long‑term therapy. - Psychosis: visual hallucinations or delusional thinking, particularly in older patients. - Severe hypotension: marked blood pressure drop leading to syncope. - Anaphylactic reaction: rare but potentially life‑threatening allergic response requiring immediate medical attention.

When prescribing Carbidopa/Levodopa, clinicians should consider several safety measures. - Dose titration: start with a low dose and increase gradually to minimize gastrointestinal and cardiovascular reactions. - Monitor blood pressure: watch for orthostatic changes, especially in the elderly. - Assess psychiatric status: observe for hallucinations, confusion, or mood alterations. - Renal/hepatic impairment: adjust dosing or monitor closely in patients with organ dysfunction. - Store at room temperature: keep in the original container, protect from moisture and light.

Carbidopa/Levodopa may interact with several drug classes; awareness helps avoid adverse outcomes.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis due to excessive catecholamine levels. - Antipsychotics (e.g., haloperidol): may antagonize dopamine receptors and reduce therapeutic efficacy. - Antihypertensive agents: additive hypotensive effect leading to dizziness or syncope.

Moderate Interactions (Monitor Closely): - SSRIs/SNRIs: potential for serotonin syndrome when combined with MAO‑B inhibitors. - Iron supplements: chelation reduces levodopa absorption; separate administration by at least two hours. - High‑protein meals: compete for transport across the intestinal wall, decreasing levodopa bioavailability.